Table of Contents
Thrombosis
Volume 2013 (2013), Article ID 516420, 9 pages
http://dx.doi.org/10.1155/2013/516420
Review Article

The Role of Thrombophilia in Pregnancy

1Brigham and Women’s Hospital, Division of Hematology, 75 Francis Street, Boston, MA 02115, USA
2Dana-Farber Cancer Institute, Department of Hematology and Medical Oncology, 450 Brookline Avenue, Smith 353, Boston, MA 02115, USA

Received 7 July 2013; Accepted 13 November 2013

Academic Editor: Edith Nutescu

Copyright © 2013 Elisabeth M. Battinelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Heit, C. E. Kobbervig, A. H. James, T. M. Petterson, K. R. Bailey, and L. J. Melton III, “Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study,” Annals of Internal Medicine, vol. 143, no. 10, pp. 697–706, 2005. View at Google Scholar · View at Scopus
  2. K. A. Bremme, “Haemostatic changes in pregnancy,” Best Practice and Research, vol. 16, no. 2, pp. 153–168, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Antovic, M. Blombäck, K. Bremme, and S. He, “The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism,” Blood Coagulation and Fibrinolysis, vol. 13, no. 3, pp. 181–186, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Cerneca, G. Ricci, R. Simeone, M. Malisano, S. Alberico, and S. Guaschino, “Coagulation and fibrinolysis changes in normal pregnancy increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 73, no. 1, pp. 31–36, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Z. Goldhaber and V. F. Tapson, “A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis,” American Journal of Cardiology, vol. 93, no. 2, pp. 259–262, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. N. S. Macklon and I. A. Greer, “The deep venous system in the puerperium: an ultrasound study,” British Journal of Obstetrics and Gynaecology, vol. 104, no. 2, pp. 198–200, 1997. View at Google Scholar · View at Scopus
  7. J. S. Ginsberg, P. Brill-Edwards, R. F. Burrows et al., “Venous thrombosis during pregnancy: leg and trimester of presentation,” Thrombosis and Haemostasis, vol. 67, no. 5, pp. 519–520, 1992. View at Google Scholar · View at Scopus
  8. A. H. James, M. G. Jamison, L. R. Brancazio, and E. R. Myers, “Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality,” American Journal of Obstetrics and Gynecology, vol. 194, no. 5, pp. 1311–1315, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Pabinger, H. Grafenhofer, P. A. Kyrle et al., “Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism,” Blood, vol. 100, no. 3, pp. 1060–1062, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Opatrny, M. David, S. R. Kahn, I. Shrier, and E. Rey, “Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis,” Journal of Rheumatology, vol. 33, no. 11, pp. 2214–2221, 2006. View at Google Scholar · View at Scopus
  12. A. A. Long, J. S. Ginsberg, P. Brill-Edwards et al., “The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study,” Thrombosis and Haemostasis, vol. 66, no. 5, pp. 520–524, 1991. View at Google Scholar · View at Scopus
  13. R. M. Bertina, B. P. C. Koeleman, T. Koster et al., “Mutation in blood coagulation factor V associated with resistance to activated protein C,” Nature, vol. 369, no. 6475, pp. 64–67, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. S. R. Poort, F. R. Rosendaal, P. H. Reitsma, and R. M. Bertina, “A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis,” Blood, vol. 88, no. 10, pp. 3698–3703, 1996. View at Google Scholar · View at Scopus
  15. C. Otto and W. O. Richter, “Hemostatic factors and the risk of myocardial infarction,” The New England Journal of Medicine, vol. 333, no. 6, pp. 389–390, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Gerhardt, R. E. Scharf, M. W. Beckmann et al., “Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium,” The New England Journal of Medicine, vol. 342, no. 6, pp. 374–380, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Middeldorp, E. J. Libourel, K. Hamulyák, J. D. Van Meer, and H. R. Büller, “The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden,” British Journal of Haematology, vol. 113, no. 2, pp. 553–555, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Robertson, O. Wu, P. Langhorne et al., “Thrombophilia in pregnancy: a systematic review,” British Journal of Haematology, vol. 132, no. 2, pp. 171–196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Benedetto, L. Marozio, A. M. Tavella, L. Salton, S. Grivon, and F. Di Giampaolo, “Coagulation disorders in pregnancy: acquired and inherited thrombophilias,” Annals of the New York Academy of Sciences, vol. 1205, pp. 106–117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Cotter, A. M. Molloy, J. M. Scott, and S. F. Daly, “Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia,” American Journal of Obstetrics and Gynecology, vol. 185, no. 4, pp. 781–785, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. F. J. M. Van der Meer, T. Koster, J. P. Vandenbroucke, E. Briët, and F. R. Rosendaal, “The Leiden Thrombophilia Study (LETS),” Thrombosis and Haemostasis, vol. 78, no. 1, pp. 631–635, 1997. View at Google Scholar · View at Scopus
  22. J. R. Meinardi, S. Middeldorp, P. J. de Kam et al., “Increased risk for fetal loss in carriers of the factor V Leiden mutation,” Annals of Internal Medicine, vol. 130, no. 9, pp. 736–739, 1999. View at Google Scholar · View at Scopus
  23. D. Tormene, P. Simioni, P. Prandoni et al., “The risk of fetal loss in family members of probands with factor V Leiden mutation,” Thrombosis and Haemostasis, vol. 82, no. 4, pp. 1237–1239, 1999. View at Google Scholar · View at Scopus
  24. O. Kocher, C. Cirovic, E. Malynn et al., “Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients,” American Journal of Clinical Pathology, vol. 127, no. 1, pp. 68–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Sottilotta, V. Oriana, C. Latella et al., “Genetic prothrombotic risk factors in women with unexplained pregnancy loss,” Thrombosis Research, vol. 117, no. 6, pp. 681–684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Lissalde-Lavigne, P. Fabbro-Peray, E. Cochery-Nouvellon et al., “Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control “NOHA First” study,” Journal of Thrombosis and Haemostasis, vol. 3, no. 10, pp. 2178–2184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. Rodger, M. T. Betancourt, P. Clark et al., “The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies,” PLoS Medicine, vol. 7, no. 6, Article ID e1000292, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Rey, S. R. Kahn, M. David, and I. Shrier, “Thrombophilic disorders and fetal loss: a meta-analysis,” The Lancet, vol. 361, no. 9361, pp. 901–908, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. F. E. Preston, F. R. Rosendaal, I. D. Walker et al., “Increased fetal loss in women with heritable thrombophilia,” The Lancet, vol. 348, no. 9032, pp. 913–916, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Roqué, M. J. Paidas, E. F. Funai, E. Kuczynski, and C. J. Lockwood, “Maternal thrombophilias are not associated with early pregnancy loss,” Thrombosis and Haemostasis, vol. 91, no. 2, pp. 290–295, 2004. View at Google Scholar · View at Scopus
  31. Z. Alfirevic, D. Roberts, and V. Martlew, “How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 101, no. 1, pp. 6–14, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. J. G. Ray and C. A. Laskin, “Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review,” Placenta, vol. 20, no. 7, pp. 519–529, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Brenner, N. Lanir, and I. Thaler, “HELLP syndrome associated with factor V R506Q mutation,” British Journal of Haematology, vol. 92, no. 4, pp. 999–1001, 1996. View at Google Scholar · View at Scopus
  34. M. G. van Pampus, G. A. Dekker, H. Wolf et al., “High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia,” American Journal of Obstetrics and Gynecology, vol. 180, no. 5, pp. 1146–1150, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. I. P. Kosmas, A. Tatsioni, and J. P. A. Ioannidis, “Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis,” Journal of Hypertension, vol. 21, no. 7, pp. 1221–1228, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Dudding, J. Heron, A. Thakkinstian et al., “Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis,” Journal of Thrombosis and Haemostasis, vol. 6, no. 11, pp. 1868–1875, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. T. E. Dudding and J. Attia, “The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis,” Thrombosis and Haemostasis, vol. 91, no. 4, pp. 700–711, 2004. View at Google Scholar · View at Scopus
  38. J. Lin and P. August, “Genetic thrombophilias and preeclampsia: a meta-analysis,” Obstetrics and Gynecology, vol. 105, no. 1, pp. 182–192, 2005. View at Google Scholar · View at Scopus
  39. A. V. D'Elia, L. Driul, R. Giacomello et al., “Frequency of factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in preeclampsia,” Gynecologic and Obstetric Investigation, vol. 53, no. 2, pp. 84–87, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. E. R. Morrison, Z. H. Miedzybrodzka, D. M. Campbell et al., “Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review,” Thrombosis and Haemostasis, vol. 87, no. 5, pp. 779–785, 2002. View at Google Scholar · View at Scopus
  41. R. M. Silver, Y. Zhao, C. Y. Spong et al., “Prothrombin gene G20210A mutation and obstetric complications,” Obstetrics and Gynecology, vol. 115, no. 1, pp. 14–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics, “ACOG Practice Bulletin No. 111: inherited thrombophilias in pregnancy,” Obstetrics and Gynecology, vol. 115, no. 4, pp. 877–887, 2010. View at Google Scholar · View at Scopus
  43. A. E. Fogerty and J. M. Connors, “Management of inherited thrombophilia in pregnancy,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 16, no. 6, pp. 464–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. L. R. Brancazio, K. A. Roperti, R. Stierer, and S. A. Laifer, “Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy,” American Journal of Obstetrics and Gynecology, vol. 173, no. 4, pp. 1240–1245, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Sephton, R. G. Farquharson, J. Topping et al., “A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy,” Obstetrics and Gynecology, vol. 101, no. 6, pp. 1307–1311, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. S. M. Bates, A. Greer, S. Middeldorp et al., “VTE, thrombophilia, antithrombotic therapy, and pregnancy—antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, pp. e691–e736, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. A. James and Committee on Practice Bulletins—Obstetrics, “Practice Bulletin 123: thromboembolism in pregnancy,” Obstetrics and Gynecology, vol. 118, pp. 718–729, 2011. View at Google Scholar
  48. Y. Dargaud, L. Rugeri, M. C. Vergnes et al., “A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study,” British Journal of Haematology, vol. 145, no. 6, pp. 825–835, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Brill-Edwards, J. S. Ginsberg, M. Gent et al., “Safety of withholding heparin in pregnant women with a history of venous thromboembolism,” The New England Journal of Medicine, vol. 343, no. 20, pp. 1439–1444, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. I. A. Greer and C. Nelson-Piercy, “Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy,” Blood, vol. 106, no. 2, pp. 401–407, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. J.-C. Gris, E. Mercier, I. Quéré et al., “Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder,” Blood, vol. 103, no. 10, pp. 3695–3699, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Folkeringa, J. L. P. Brouwer, F. J. Korteweg et al., “Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women,” British Journal of Haematology, vol. 136, no. 4, pp. 656–661, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Coppens, N. Folkeringa, M. J. Teune et al., “Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations,” Journal of Thrombosis and Haemostasis, vol. 5, no. 7, pp. 1444–1448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. A. M. Badawy, M. Khiary, L. S. Sherif, M. Hassan, A. Ragab, and I. Abdelall, “Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology,” Journal of Obstetrics and Gynaecology, vol. 28, no. 3, pp. 280–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Dolitzky, A. Inbal, Y. Segal, A. Weiss, B. Brenner, and H. Carp, “A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages,” Fertility and Sterility, vol. 86, no. 2, pp. 362–366, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. J. E. Warren, S. E. Simonsen, D. W. Branch, T. F. Porter, and R. M. Silver, “Thromboprophylaxis and pregnancy outcomes in asymptomatic women with inherited thrombophilias,” American Journal of Obstetrics and Gynecology, vol. 200, no. 3, pp. e281–e285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Mantha, K. A. Bauer, and J. I. Zwicker, “Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review,” Journal of Thrombosis and Haemostasis, vol. 8, no. 2, pp. 263–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Rai, H. Cohen, M. Dave, and L. Regan, “Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies),” British Medical Journal, vol. 314, no. 7076, pp. 253–257, 1997. View at Google Scholar · View at Scopus
  59. W. H. Kutteh, “Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone,” American Journal of Obstetrics and Gynecology, vol. 174, no. 5, pp. 1584–1589, 1996. View at Publisher · View at Google Scholar · View at Scopus
  60. R. G. Farquharson, S. Quenby, and M. Greaves, “Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment,” Obstetrics and Gynecology, vol. 100, no. 3, pp. 408–413, 2002. View at Google Scholar